<link rel="stylesheet" href="https://bootswatch.com/4/flatly/bootstrap.min.css">
<script src="https://ajax.googleapis.com/ajax/libs/jquery/3.5.1/jquery.min.js"></script>
<script src="https://cdnjs.cloudflare.com/ajax/libs/popper.js/1.16.0/umd/popper.min.js"></script>
<script src="https://maxcdn.bootstrapcdn.com/bootstrap/4.5.2/js/bootstrap.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1">
<p id="home">6/28/2022</p>
<p><strong> <em>Summary: New Data in 4 studies, Expedited timeline in 4 studies, 12 new studies added, FDA accepted application for 4 studies</em> </strong></p>
<h1>Clinical Trials Weekly Digest: Lung Cancer</h1>

<h4><a href="#clinical">Clinical Results</a></h4>
<h4><a href="#existing_lc">Existing Trials</a></h4>
<h4><a href="#new_lc">New Trials</a></h4>
<h4><a href="#approvals">Drug Approvals/Applications</a></h4>

<br>
<!-- ############################### -->
<!-- ############################### -->
<!-- ###### CLINICAL RESULTS ####### -->
<!-- ############################### -->
<!-- ############################### -->

<h2 id="clinical">Clinical Results Press Releases</h2>
<h4><a href="#home">Home</a></h4>
<table border="1" summary="Long-term goals table" width="100%" cellspacing="0" cellpadding="0">
  <thead>
    <tr>
      <th>
        <h3>Company</h3>
      </th>
      <th>
        <h3>Update</h3>
      </th>
      <th>
        <h3>Trial ID</h3>
      </th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>SELLAS Life Sciences</td>
      <td>SELLAS Life Sciences Provides Clinical Update for GFH009 Ongoing Phase 1 Clinical Trial</td>
      <td>NCT04588922</td>
    </tr>
    <tr>
      <td>Ascletis</td>
      <td>Ascletis' Subcutaneous PD-L1 Antibody ASC22 Demonstrated Potential of Functional Cure of Chronic Hepatitis B as 42.9% of Patients with Baseline HBsAg100 IU/mL Obtained Sustained HBsAg Loss</td>
      <td>NCT04465890</td>
    </tr>
    <tr>
      <td>Antengene</td>
      <td>Antengene Announces Clinical Trial Collaboration with BeiGene to Evaluate Selinexor in Combination with Tislelizumab in T and NK-Cell Lymphoma</td>
      <td></td>
    </tr>
    <tr>
      <td>Calithera Biosciences</td>
      <td>Calithera Biosciences Begins Phase II Trial of Mivavotinib in DLBCL</td>
      <td>NCT05319028</td>
    </tr>
    <tr>
      <td>Transgene and BioInvent</td>
      <td>Transgene and BioInvent Announce Positive Progress for BT-001</td>
      <td>NCT04725331</td>
    </tr>
    <tr>
      <td>Biomea Fusion√Ç</td>
      <td>Biomea doses first subject in multiple myeloma cohort of Phase I trial</td>
      <td>COVALENT-101 (NCT05153330)</td>
    </tr>
    <tr>
      <td>Ultimovac</td>
      <td>Ultimovacs cancer vaccine demonstrates overall survival in Phase I melanoma trial</td>
      <td>NCT03538314</td>
    </tr>
  </tbody>
</table>

<!-- ############################### -->
<!-- ############################### -->
<!-- ######### EXISTING LC ######### -->
<!-- ############################### -->
<!-- ############################### -->

<br>
<h2 id="existing_lc">Existing Trials</h2>
<h4><a href="#home">Home</a></h4>
<table border="1" summary="Long-term goals table" width="100%" cellspacing="0" cellpadding="0">
  <thead>
    <tr>
      <th>
        <h3>Update</h3>
      </th>
      <th>
        <h3>Condition</h3>
      </th>
      <th>
        <h3>Sponsor</h3>
      </th>
      <th>
        <h3>Phase</h3>
      </th>
      <th>
        <h3>Intervention</h3>
      </th>
      <th>
        <h3>Trial ID</h3>
      </th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><strong>Completion Date moved earlier by 196 days</strong></td>
      <td>Pleural Mesothelioma; Non-small Cell Lung Cancer</td>
      <td>Sanofi</td>
      <td>Phase 2</td>
      <td><button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_13">THOR-707; Pembrolizumab; Carboplatin; Cisplatin; Nab-paclitaxel; Pemetrexed</button></td>
      <td>NCT04914897</td>
    </tr>
    <tr>
      <td><strong>Completion Date moved earlier by 191 days; Enrollment decreased by: 45; Trial completed</strong></td>
      <td>NSCLC</td>
      <td>Eli Lilly and Company</td>
      <td>Phase 1</td>
      <td><button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_14">Ramucirumab; Necitumumab; Osimertinib</button></td>
      <td>NCT02789345</td>
    </tr>
    <tr>
      <td><strong>Completion Date moved earlier by 120 days; Primary Completion Date moved earlier by 28 days</strong></td>
      <td>Advanced Solid Tumors; HER2+ advanced solid tumors</td>
      <td>MacroGenics</td>
      <td>Phase 1</td>
      <td><button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_15">tebotelimab; margetuximab</button></td>
      <td>NCT03219268</td>
    </tr>
    <tr>
      <td><strong>Completion Date moved earlier by 112 days; Now recruiting; Start Date moved earlier by 111 days</strong></td>
      <td>Metastatic cancers</td>
      <td>UNICANCER</td>
      <td>Phase 3</td>
      <td><button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_16">Reduced dose intensity of IO</button></td>
      <td>NCT05078047</td>
    </tr>
    <tr>
      <td><strong>Now recruiting</strong></td>
      <td>Limited Stage SCLC phase III clincal study; anti-PD1 antibody used in combination with various chemotherapies</td>
      <td>Shanghai Henlius Biotech</td>
      <td>Phase 3</td>
      <td><button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_17">HLX10; carboplatin/cisplatin-etoposide; Thoracic radiotherapy; Placebo; Prophylactic Cranial Irradiation (PCI)</button></td>
      <td>NCT05353257</td>
    </tr>
    <tr>
      <td><strong>Completion Date now May 20 2022; Trial completed</strong></td>
      <td>Newly Diagnosed Stage III NSCLC that cannot be removed by surgery</td>
      <td>Radiation Therapy Oncology Group</td>
      <td>Phase 3</td>
      <td><button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_18">Cetuximab; Carboplatin; Paclitaxel; 60 Gy RT; 74 Gy RT</button></td>
      <td>NCT00533949</td>
    </tr>
    <tr>
      <td><strong>Changed status from recruiting to active</strong></td>
      <td>Platinum-resistant small-cell lung cancer (SCLC)</td>
      <td>EMD Serono Research & Development Institute Inc.</td>
      <td>Phase 2</td>
      <td><button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_19">Berzosertib; Berzosertib; Topotecan</button></td>
      <td>NCT04768296</td>
    </tr>
    <tr>
      <td><strong>Now recruiting; Start Date moved earlier by 30 days</strong></td>
      <td>Advanced (NSCLC) harboring a KRAS G12C mutation who have been previously treated with a platinum-based chemotherapy and immune checkpoint inhibitor therapy (in combination or exclusively)</td>
      <td>Novartis Pharmaceuticals</td>
      <td>Phase 3</td>
      <td><button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_20">JDQ443; docetaxel</button></td>
      <td>NCT05132075</td>
    </tr>
    <tr>
      <td><strong>Enrollment decreased by: 20; Changed status from recruiting to active</strong></td>
      <td>Advanced NSCLC; targeting EGFR mutations</td>
      <td>Duke University</td>
      <td>Phase 2</td>
      <td><button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_21">osimertinib</button></td>
      <td>NCT03434418</td>
    </tr>
    <tr>
      <td><strong>Start Date pushed later by 92 days</strong></td>
      <td>Advanced or metastatic non-small-cell lung cancer (NSCLC) without actionable genomic alterations</td>
      <td>Gilead Sciences</td>
      <td>Phase 2</td>
      <td><button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_22">Sacituzumab Govitecan-hziy (SG); Pembrolizumab; Carboplatin; Cisplatin</button></td>
      <td>NCT05186974</td>
    </tr>
    <tr>
      <td><strong>Primary Completion Date pushed later by 409 days</strong></td>
      <td>SCLC</td>
      <td>Amgen</td>
      <td>Phase 1</td>
      <td><button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_23">AMG 757; Pembrolizumab; CRS Mitigation Strategies</button></td>
      <td>NCT03319940</td>
    </tr>
    <tr>
      <td><strong>Enrollment decreased by: 41; Changed status from suspended to active; Primary Completion Date moved earlier by 93 days</strong></td>
      <td>Metastatic NSCLC patients with solid tumors</td>
      <td>Stanford University</td>
      <td>Phase 2</td>
      <td><button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_24">Immunotherapy (standard of care); Image Guided Radiation Therapy; Laboratory Biomarker Analysis</button></td>
      <td>NCT03176173</td>
    </tr>
    <tr>
      <td><strong>Changed status from recruiting to active</strong></td>
      <td>NSCLC patients with dose-limiting toxicities</td>
      <td>Amgen</td>
      <td>Phase 1</td>
      <td><button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_25">AMG 160</button></td>
      <td>NCT04822298</td>
    </tr>
    <tr>
      <td><strong>Enrollment decreased by: 11</strong></td>
      <td>Unresectable advanced and/or recurrent ALK-positive NSCLC with resistance or intolerance to at least 1 prior ALK inhibitor treatment</td>
      <td>Pfizer</td>
      <td>Phase 4</td>
      <td><button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_26">Lorlatinib</button></td>
      <td>NCT04541706</td>
    </tr>
    <tr>
      <td><strong>Now recruiting</strong></td>
      <td>Non-small cell lung cancer previously treated with PD-1 and/or PD-L1 immune checkpoint inhibitors</td>
      <td>City of Hope Medical Center</td>
      <td>Phase 1</td>
      <td><button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_27">Antineoplastic Immune Cell; Atezolizumab; Biospecimen Collection; Cyclophosphamide; Fludarabine</button></td>
      <td>NCT05334329</td>
    </tr>
    <tr>
      <td><strong>Enrollment increased by: 74; Changed status from recruiting to active</strong></td>
      <td>EGFR positive locally advanced or metastatic non-small cell lung cancer (NSCLC)</td>
      <td>Janssen Research & Development LLC</td>
      <td>Phase 3</td>
      <td><button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_28">Amivantamab; Osimertinib; Lazertinib; Placebo</button></td>
      <td>NCT04487080</td>
    </tr>
    <tr>
      <td><strong>Primary Completion Date moved earlier by 33 days</strong></td>
      <td>NSCLC patients following first-line osimertinib treatment</td>
      <td>AstraZeneca</td>
      <td>Phase 3</td>
      <td><button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_29">Osimertinib (AZD9291) pemetrexed cisplatin or carboplatin; Placebo for osimertinib (AZD9291) pemetrexed cisplatin or carboplatin</button></td>
      <td>NCT04765059</td>
    </tr>
    <tr>
      <td><strong>Changed status from recruiting to active</strong></td>
      <td>Stage IV or recurrent NSCLC</td>
      <td>M.D. Anderson Cancer Center</td>
      <td>Early Phase 1</td>
      <td><button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_30">Brigatinib; Local Consolidation Therapy</button></td>
      <td>NCT03707938</td>
    </tr>
    <tr>
      <td><strong>Primary Completion Date pushed later by 365 days</strong></td>
      <td>Stage IV or recurrent NSCLC EGFR or HER2 exon 20 mutation</td>
      <td>M.D. Anderson Cancer Center</td>
      <td>Phase 2</td>
      <td><button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_31">Poziotinib</button></td>
      <td>NCT03066206</td>
    </tr>
    <tr>
      <td><strong>Enrollment decreased by: 264; Changed status from recruiting to active</strong></td>
      <td>Stage II-III NSCLC patients who are MRD-positive following curative intent therapy</td>
      <td>AstraZeneca</td>
      <td>Phase 3</td>
      <td><button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_32">Durvalumab; Placebo</button></td>
      <td>NCT04642469</td>
    </tr>
    <tr>
      <td><strong>Enrollment decreased by: 246; Changed status from recruiting to active</strong></td>
      <td>Completely resected stage II-III NSCLC who are MRD+ post surgery</td>
      <td>AstraZeneca</td>
      <td>Phase 3</td>
      <td><button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_33">Durvalumab + SoC chemotherapy; Placebo + SoC chemotherapy</button></td>
      <td>NCT04385368</td>
    </tr>
    <tr>
      <td><strong>Now recruiting</strong></td>
      <td>Solid tumors</td>
      <td>SOTIO Biotech AG</td>
      <td>Phase 2</td>
      <td><button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_34">SOT101; Pembrolizumab</button></td>
      <td>NCT05256381</td>
    </tr>
    <tr>
      <td><strong>Primary Completion Date pushed later by 195 days</strong></td>
      <td>Advanced cancers</td>
      <td>Novartis Pharmaceuticals</td>
      <td>Phase 1</td>
      <td><button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_35">NZV930; PDR001; NIR178</button></td>
      <td>NCT03549000</td>
    </tr>
    <tr>
      <td><strong>Start Date moved earlier by 9 days</strong></td>
      <td>Advanced Solid Tumor</td>
      <td>STCube Inc.</td>
      <td>Phase 1</td>
      <td><button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_36">hSTC810</button></td>
      <td>NCT05231746</td>
    </tr>
    <tr>
      <td><strong>Changed status from recruiting to active; Primary Completion Date pushed later by 274 days</strong></td>
      <td>Biomarker-selected adult subjects with metastatic NSCLC who are PD-1/PD-L1 inhibitor naive and have progressed on a platinum based chemotherapy regimen</td>
      <td>Jounce Therapeutics Inc.</td>
      <td>Phase 2</td>
      <td><button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_37">JTX-4014; Vopratelimab</button></td>
      <td>NCT04549025</td>
    </tr>
    <tr>
      <td><strong>Completion Date pushed later by 112 days</strong></td>
      <td>Metastatic NSCLC patients with solid tumors</td>
      <td>Novartis Pharmaceuticals</td>
      <td>Phase 3</td>
      <td><button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_38">Ceritinib; Pemetrexed; Cisplatin; Carboplatin</button></td>
      <td>NCT01828099</td>
    </tr>
    <tr>
      <td><strong>Completion Date pushed later by 147 days; Enrollment decreased by: 15; Trial completed; Primary Completion Date pushed later by 331 days; Start Date moved earlier by 40 days</strong></td>
      <td>SCLC</td>
      <td>Jiangsu HengRui Medicine Co. Ltd.</td>
      <td>Phase 1</td>
      <td><button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_39">1.Experimental: A (Part 1): Fluzoparib and SHR -1316; 2.Experimental: B (Part 1): Fluzoparib and SHR -1316; 3.Experimental: C (Part 2): Fluzoparib and SHR -1316 Expansion</button></td>
      <td>NCT04041011</td>
    </tr>
    <tr>
      <td><strong>Completion Date pushed later by 152 days</strong></td>
      <td>(EGFRm+) locally advanced or metastatic Non Small Cell Lung Cancer (NSCLC)</td>
      <td>Janssen Research & Development LLC</td>
      <td>Phase 1|Phase 2</td>
      <td><button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_40">Lazertinib</button></td>
      <td>NCT04075396</td>
    </tr>
    <tr>
      <td><strong>Completion Date pushed later by 184 days; Primary Completion Date pushed later by 730 days</strong></td>
      <td>Stage IV LC patients undergoing surgery</td>
      <td>Eben Rosenthal</td>
      <td>Phase 1|Phase 2</td>
      <td><button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_41">Near-Infrared Fluorescence Imaging; Panitumumab-IRDye800; Pharmacokinetic Study; Therapeutic Conventional Surgery</button></td>
      <td>NCT03582124</td>
    </tr>
    <tr>
      <td><strong>Completion Date pushed later by 184 days</strong></td>
      <td>ES-SCLC treated with durvalumab in combination with platinum-etoposide as first-line treatment</td>
      <td>AstraZeneca</td>
      <td>Phase 3</td>
      <td><button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_42">Durvalumab; Cisplatin; Etoposide; Carboplatin</button></td>
      <td>NCT04712903</td>
    </tr>
    <tr>
      <td><strong>Completion Date pushed later by 243 days</strong></td>
      <td>EGFRm+ locally advanced or metastatic Non Small Cell Lung Cancer (NSCLC)</td>
      <td>Boehringer Ingelheim</td>
      <td>Phase 3</td>
      <td><button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_43">afatinib</button></td>
      <td>NCT01853826</td>
    </tr>
    <tr>
      <td><strong>Completion Date pushed later by 365 days</strong></td>
      <td>LC patients with RET; ROS1/NTRK fusion; MET/AXL gene changes</td>
      <td>Memorial Sloan Kettering Cancer Center</td>
      <td>Phase 2</td>
      <td><button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_44">Cabozantinib</button></td>
      <td>NCT01639508</td>
    </tr>
    <tr>
      <td><strong>Completion Date pushed later by 365 days</strong></td>
      <td>Immune checkpoint inhibitor-related colitis in patients with genitourinary cancer or melanoma</td>
      <td>M.D. Anderson Cancer Center</td>
      <td>Phase 1|Phase 2</td>
      <td><button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_45">Infliximab; Vedolizumab</button></td>
      <td>NCT04407247</td>
    </tr>
    <tr>
      <td><strong>Completion Date pushed later by 366 days</strong></td>
      <td>NSCLC who have not been cured by other treatments</td>
      <td>Daiichi Sankyo Co. Ltd.</td>
      <td>Phase 1</td>
      <td><button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_46">Datopotamab Deruxtecan (Dato-DXd)</button></td>
      <td>NCT03401385</td>
    </tr>
    <tr>
      <td><strong>Completion Date pushed later by 547 days; Primary Completion Date pushed later by 912 days</strong></td>
      <td>Malignant mesothelioma; non-small cell lung cancer or any other malignancy with pleural disease undergoing surgery</td>
      <td>Roswell Park Cancer Institute</td>
      <td>Phase 1</td>
      <td><button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_47">Light Dosimetry for Intranoperative Therapy; Photodynamic Therapy; Porfimer Sodium</button></td>
      <td>NCT03678350</td>
    </tr>
    <tr>
      <td><strong>Completion Date pushed later by 607 days; Changed status from recruiting to active; Primary Completion Date pushed later by 699 days</strong></td>
      <td>EGFR mutation; T790M negative NSCLC who have progressed after EGFR TKI treatment</td>
      <td>Sunshine Lake Pharma Co. Ltd.</td>
      <td>Phase 1|Phase 2</td>
      <td><button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_48">CT053PTSA; Gefitinib</button></td>
      <td>NCT03758287</td>
    </tr>
    <tr>
      <td><strong>Completion Date pushed later by 650 days</strong></td>
      <td>Advanced melanoma lung cancer or kidney cancer</td>
      <td>University of Washington</td>
      <td>Phase 2</td>
      <td><button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_49">Atezolizumab; Hypofractionated Radiation Therapy; Laboratory Biomarker Analysis; Nelfinavir Mesylate; Nivolumab; Pembrolizumab</button></td>
      <td>NCT03050060</td>
    </tr>
    <tr>
      <td><strong>Completion Date pushed later by 701 days; Primary Completion Date pushed later by 882 days</strong></td>
      <td>Advanced or metastatic HER2-expressing tumors</td>
      <td>Acepodia Biotech Inc.</td>
      <td>Phase 1</td>
      <td><button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_50">ACE1702; Cyclophosphamide; Fludarabine</button></td>
      <td>NCT04319757</td>
    </tr>
    <tr>
      <td><strong>Completion Date pushed later by 710 days; Primary Completion Date pushed later by 286 days</strong></td>
      <td>Advanced Solid Tumor</td>
      <td>Bristol-Myers Squibb</td>
      <td>Phase 1|Phase 2</td>
      <td><button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_51">BMS-986315; nivolumab; cetuximab</button></td>
      <td>NCT04349267</td>
    </tr>
    <tr>
      <td><strong>Completion Date pushed later by 1130 days; Changed status from unknown status to active</strong></td>
      <td>Non-small Cell Lung Cancer; Melanoma; and Mismatch-Repair Proficient Colorectal Cancer</td>
      <td>Syndax Pharmaceuticals</td>
      <td>Phase 1|Phase 2</td>
      <td><button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_52">entinostat; pembrolizumab</button></td>
      <td>NCT02437136</td>
    </tr>
  </tbody>
</table>
<!-- THE MODAL -->
<div class="modal fade" id="modal_13" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
      <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class="modal-body">
        <table class="table table-striped">
          <thead>
            <tr>
              <th colspan="1">Arm Group Type</th>
              <th colspan="1">Arm Group Description</th>
              <th colspan="1">Arm Group Intervention</th>
              <th colspan="1">Primary Outcome Measure</th>
              <th colspan="1">Primary Outcome Description</th>
              <th colspan="1">Primary Outcome Time Frame</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td>Experimental</td>
              <td>SAR444245 + pembrolizumab on day 1 of a 21-day treatment cycle (up 35 cycles).|SAR444245 + pembrolizumab on day 1 of a 21-day treatment cycle (up 35 cycles).|SAR444245 + pembrolizumab on day 1 of a 21 day treatment cycle (up to 35 cycles) Carboplatin/cisplatin on day 1 of a 21-day treatment cycle (up to 4 cycles) Pemetrexed on day 1 of a 21-day treatment cycle (until progressive disease or intolerability)|SAR444245 + pembrolizumab on day 1 of a 21-day treatment cycle (up 35 cycles).|SAR444245 + pembrolizumab (up to 35 cycles) and nab-paclitaxel (up to 6 cycles) on day 1 of a 21-day treatment cycle.|SAR444245 + pembrolizumab on day 1 of a 21-day treatment cycle (up 35 cycles).</td>
              <td>Drug: Pembrolizumab; Drug: Cisplatin; Drug: Nab-paclitaxel; Drug: THOR-707; Drug: Carboplatin; Drug: Pemetrexed</td>
              <td>Objective response rate (ORR)</td>
              <td>Objective response rate (ORR) defined as the proportion of participants who have a confirmed complete response (CR) or partial response (PR) derived based on Investigator's assessment per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for Cohort A1 Cohort A2 Cohort A3 Cohort B1 and Cohort B2; per modified RECIST (mRECIST) for Cohort C1.</td>
              <td>Baseline to the date of first documented progression or initiation of subsequent anticancer therapy or approximatively 9 months after the last participant receive first dose</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_14" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
      <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class="modal-body">
        <table class="table table-striped">
          <thead>
            <tr>
              <th colspan="1">Arm Group Type</th>
              <th colspan="1">Arm Group Description</th>
              <th colspan="1">Arm Group Intervention</th>
              <th colspan="1">Primary Outcome Measure</th>
              <th colspan="1">Primary Outcome Description</th>
              <th colspan="1">Primary Outcome Time Frame</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td>Experimental</td>
              <td>Dose Finding: Ramucirumab given intravenously (IV) on day 1 every 2 weeks (Q2W) and osimertinib given orally daily during each 14 day cycle.||Expansion: Ramucirumab given IV on day 1 Q2W and osimertinib given orally daily during each 14 day cycle.|Dose Finding: Necitumumab given IV on days 1 and 8 every 3 weeks (Q3W) and osimertinib given orally daily during each 21 day cycle.||Expansion: Necitumumab given IV on days 1 and 8 Q3W and osimertinib given orally daily during each 21 day cycle.</td>
              <td>Drug: Ramucirumab; Drug: Necitumumab; Drug: Osimertinib</td>
              <td>Number of Participants with Dose Limiting Toxicities (DLTs)</td>
              <td></td>
              <td>Up to Two Cycles (Up to 21 Day Cycles)</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_15" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
      <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class="modal-body">
        <table class="table table-striped">
          <thead>
            <tr>
              <th colspan="1">Arm Group Type</th>
              <th colspan="1">Arm Group Description</th>
              <th colspan="1">Arm Group Intervention</th>
              <th colspan="1">Primary Outcome Measure</th>
              <th colspan="1">Primary Outcome Description</th>
              <th colspan="1">Primary Outcome Time Frame</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td>Experimental</td>
              <td>Tebotelimab administered IV once every 2 weeks for up to 96 weeks|Tebotelimab administered IV once every 2 weeks for up to 96 weeks|Tebotelimab administered IV once every 2 weeks for up to 96 weeks|Tebotelimab administered IV once every 2 weeks for up to 96 weeks|Tebotelimab administered IV once every 2 weeks for up to 96 weeks|Tebotelimab administered IV once every 2 weeks for up to 96 weeks|Tebotelimab administered IV once every 2 weeks for up to 96 weeks|Tebotelimab administered IV once every 2 weeks for up to 96 weeks|Tebotelimab administered in combination with margetuximab IV once every 3 weeks for up to 32 3-week cycles|Tebotelimab administered in combination with margetuximab IV once every 3 weeks for up to 32 3-week cycles</td>
              <td>Biological: tebotelimab; Biological: margetuximab</td>
              <td>Incidence of Treatment-Emergent Adverse Events (TEAE) as assessed by CTCAE v4.03 (tebotelimab monotherapy)|Maximum Tolerated Dose|Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE v4.03 (tebotelimab plus margetuximab)</td>
              <td>maximum tolerated or maximum administered dose of tebotelimab; Safety is based on evaluation of adverse events (AEs) and serious adverse events (SAEs) from the time of study drug administration through the End of Study visit.; Safety</td>
              <td>up to 24 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_16" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
      <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class="modal-body">
        <table class="table table-striped">
          <thead>
            <tr>
              <th colspan="1">Arm Group Type</th>
              <th colspan="1">Arm Group Description</th>
              <th colspan="1">Arm Group Intervention</th>
              <th colspan="1">Primary Outcome Measure</th>
              <th colspan="1">Primary Outcome Description</th>
              <th colspan="1">Primary Outcome Time Frame</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td>Experimental; No Intervention</td>
              <td>Reduced dose intensity of IO:||IO will be administered every 3 months (at the same dose levels) until disease progression unacceptable toxicity death or patient's choice or investigator's decision|Standard IO:||Continuation of IO at the same dose levels and rhythmicity until disease progression unacceptable toxicity death or patient's choice.</td>
              <td>Drug: Reduced dose intensity of IO</td>
              <td>Progression-free survival (PFS)</td>
              <td>The progression-free survival is the length of time during and after the treatment of a disease that a patient lives with the disease but it does not get worse.</td>
              <td>From randomization to disease progression or death up to 3 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_17" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
      <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class="modal-body">
        <table class="table table-striped">
          <thead>
            <tr>
              <th colspan="1">Arm Group Type</th>
              <th colspan="1">Arm Group Description</th>
              <th colspan="1">Arm Group Intervention</th>
              <th colspan="1">Primary Outcome Measure</th>
              <th colspan="1">Primary Outcome Description</th>
              <th colspan="1">Primary Outcome Time Frame</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td>Experimental; Placebo Comparator</td>
              <td>Participants will receive 4 cycles of standard-of-care chemotherapy (carboplatin/cisplatin-etoposide) plus HLX10 300 mg every 3 weeks (Q3W) concurrently with standard thoracic radiotherapy with maximum 2 years or until disease progression intolerable toxicity or other reasons specified in the protocol whichever occurs first.|Participants will receive 4 cycles of standard-of-care chemotherapy (carboplatin/cisplatin-etoposide) plus placebo every 3 weeks (Q3W) concurrently with standard thoracic radiotherapy with maximum 2 years or until disease progression intolerable toxicity or other reasons specified in the protocol whichever occurs first.</td>
              <td>Radiation: Prophylactic Cranial Irradiation (PCI); Drug: Placebo; Radiation: Thoracic radiotherapy; Drug: carboplatin/cisplatin-etoposide; Drug: HLX10</td>
              <td>Overall survival(OS</td>
              <td>the time from randomization to death due to any cause</td>
              <td>up to 36 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_18" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
      <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class="modal-body">
        <table class="table table-striped">
          <thead>
            <tr>
              <th colspan="1">Arm Group Type</th>
              <th colspan="1">Arm Group Description</th>
              <th colspan="1">Arm Group Intervention</th>
              <th colspan="1">Primary Outcome Measure</th>
              <th colspan="1">Primary Outcome Description</th>
              <th colspan="1">Primary Outcome Time Frame</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td>Experimental; Active Comparator</td>
              <td>60 Gy Radiation therapy with concurrent paclitaxel and carboplatin followed by consolidation paclitaxel and carboplatin|74 Gy Radiation therapy with concurrent paclitaxel and carboplatin followed by consolidation paclitaxel and carboplatin|60 Gy Radiation therapy with concurrent cetuximab paclitaxel and carboplatin followed by consolidation cetuximab paclitaxel and carboplatin|74 Gy Radiation therapy with concurrent cetuximab paclitaxel and carboplatin followed by consolidation cetuximab paclitaxel and carboplatin</td>
              <td>Radiation: 74 Gy RT; Radiation: 60 Gy RT; Drug: Carboplatin; Biological: Cetuximab; Drug: Paclitaxel</td>
              <td>Overall Survival</td>
              <td>Survival time is defined as time from randomization to date of death from any cause and is estimated by the Kaplan-Meier method. Patients last known to be alive are censored at the date of last contact.</td>
              <td>From randomization to last follow-up. Analysis occured after all patients were on study for 18 months. Maximum follow-up at time of analysis was 61.5 months.</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_19" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
      <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class="modal-body">
        <table class="table table-striped">
          <thead>
            <tr>
              <th colspan="1">Arm Group Type</th>
              <th colspan="1">Arm Group Description</th>
              <th colspan="1">Arm Group Intervention</th>
              <th colspan="1">Primary Outcome Measure</th>
              <th colspan="1">Primary Outcome Description</th>
              <th colspan="1">Primary Outcome Time Frame</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td>Experimental</td>
              <td>In Japan a Safety Run-in Part will be conducted. In case safety and tolerability is confirmed in the Safety Run-in part Japanese participants will enroll in the Main Part of the Phase 2. Both in the Safety Run-in and Main Part of the Phase 2 participants will receive berzosertib and topotecan until disease progression or other criteria for study intervention discontinuation are met.</td>
              <td>Drug: Topotecan; Drug: Berzosertib</td>
              <td>Main Part: Objective Response (OR) according to Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 as assessed by Independent Review Committee (IRC)|Safety Run-in Part: Number of Participants With Dose Limiting Toxicities (DLTs)|Safety Run-in Part: Number of Participants with Treatment-Emergent Adverse Events (TEAEs) Serious TEAEs and Treatment-Related TEAEs|Safety Run-in Part: Number of Participants with Clinically Significant Changes From Baseline in Vital Signs 12-Lead Electrocardiogram (ECG) Findings and Laboratory Parameters</td>
              <td></td>
              <td>Up to Cycle 1 Day 21 (each cycle is of 21 days); From first administration of study intervention up to 15 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_20" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
      <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class="modal-body">
        <table class="table table-striped">
          <thead>
            <tr>
              <th colspan="1">Arm Group Type</th>
              <th colspan="1">Arm Group Description</th>
              <th colspan="1">Arm Group Intervention</th>
              <th colspan="1">Primary Outcome Measure</th>
              <th colspan="1">Primary Outcome Description</th>
              <th colspan="1">Primary Outcome Time Frame</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td>Experimental; Active Comparator</td>
              <td>Participants will be treated with JDQ443|Participant will be treated with docetaxel following local guidelines as per standard of care and product labels</td>
              <td>Drug: JDQ443; Drug: docetaxel</td>
              <td>Progression free survival (PFS)</td>
              <td>PFS is the time from date of randomization/start of treatment to the date of event defined as the first documented progression or death due to any cause. PFS is based on central assessment and using RECIST 1.1 criteria.</td>
              <td>Approximately up to 24 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_21" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
      <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class="modal-body">
        <table class="table table-striped">
          <thead>
            <tr>
              <th colspan="1">Arm Group Type</th>
              <th colspan="1">Arm Group Description</th>
              <th colspan="1">Arm Group Intervention</th>
              <th colspan="1">Primary Outcome Measure</th>
              <th colspan="1">Primary Outcome Description</th>
              <th colspan="1">Primary Outcome Time Frame</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td>Experimental</td>
              <td></td>
              <td>Drug: osimertinib</td>
              <td>Objective response rate as assessed by the investigator using Response Evaluation Criteria In Solid Tumors RECIST 1.1 (brand name)</td>
              <td>RECIST 1.1 will be used to measure confirmed partial or complete responses to the study drug.</td>
              <td>Up to 3 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_22" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
      <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class="modal-body">
        <table class="table table-striped">
          <thead>
            <tr>
              <th colspan="1">Arm Group Type</th>
              <th colspan="1">Arm Group Description</th>
              <th colspan="1">Arm Group Intervention</th>
              <th colspan="1">Primary Outcome Measure</th>
              <th colspan="1">Primary Outcome Description</th>
              <th colspan="1">Primary Outcome Time Frame</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td>Experimental</td>
              <td>Participants assigned to Cohorts A according to tumor proportion score (TPS) status will receive SG 10 mg/kg on Days 1 and 8 of a 21-day cycle + pembrolizumab 200 mg on Day 1 of a 21-day cycle.|Participants assigned to Cohorts B according to TPS status will receive SG 10 mg/kg on Days 1 and 8 of a 21-day cycle + pembrolizumab 200 mg on Day 1 of a 21-day cycle.|Participants will receive SG (de-escalating dose levels: 10.0 mg/kg 7.5 mg/kg or 5.0 mg/kg) on Days 1 and 8 of a 21-day cycle + pembrolizumab 200 mg on Day 1 of a 21-day cycle + carboplatin area under the concentration versus time curve (AUC)5 on Day 1 of a 21-day cycle.|Participants will receive SG (either 10 mg/kg or 7.5 mg/kg) on Days 1 and 8 of a 21-day cycle + pembrolizumab 200 mg on Day 1 of a 21-day cycle + cisplatin 75 mg/m^2 on Day 1 of a 21-day cycle.|Participants assigned to Cohort C according to disease status will receive SG RP2D as determined during the safety run-in cohorts on Days 1 and 8 of a 21-day cycle + pembrolizumab 200 mg on Day 1 of a 21-day cycle + carboplatin AUC5 or cisplatin 75 mg/m^2 as determined during the safety run-in cohorts on Day 1 of a 21-day cycle.|Participants assigned to Cohort D according to disease status will receive SG RP2D as determined during the safety run-in cohorts on Days 1 and 8 of a 21-day cycle + pembrolizumab 200 mg on Day 1 of a 21-day cycle + carboplatin AUC5 or cisplatin 75 mg/m^2 as determined during the safety run-in cohorts on Day 1 of a 21-day cycle.</td>
              <td>Drug: Pembrolizumab; Drug: Sacituzumab Govitecan-hziy (SG); Drug: Cisplatin; Drug: Carboplatin</td>
              <td>Objective Response Rate as Assessed by Independent Review Committee (IRC) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1|Percentage of Participants Experiencing Dose-limiting Toxicities (DLTs) per Dose Level in the Safety Run-in Cohorts</td>
              <td></td>
              <td>Up to 22 Months; First dose date up to 21 days</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_23" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
      <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class="modal-body">
        <table class="table table-striped">
          <thead>
            <tr>
              <th colspan="1">Arm Group Type</th>
              <th colspan="1">Arm Group Description</th>
              <th colspan="1">Arm Group Intervention</th>
              <th colspan="1">Primary Outcome Measure</th>
              <th colspan="1">Primary Outcome Description</th>
              <th colspan="1">Primary Outcome Time Frame</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td>Experimental</td>
              <td>AMG 757 Monotherapy|AMG 757 with Pembrolizumab|AMG 757 with additional cytokine release syndrome (CRS) mitigation strategies|AMG 757 administration with 24-hour monitoring|AMG 757 administered in outpatient infusion centers with 8-hour monitoring||Optional wearable digital device substudy (US sites only)|AMG 757 additional dosing schedule||Optional wearable digital device substudy (US sites only)</td>
              <td>Drug: AMG 757; Drug: Pembrolizumab; Drug: CRS Mitigation Strategies</td>
              <td>Number of participants with dose limiting toxicities (DLT) for all indications|Number of participants with treatment-emergent adverse events (AEs) for all indications|Number of participants with treatment-related AEs for all indications|Number of participants with clinically significant changes in vital signs for all indications|Number of participants with significant changes in ECG for all indications|Number of participants with significant changes in physical examinations for all indications|Number of participants with significant changes in clinical laboratory tests for all indications</td>
              <td></td>
              <td>6 months; 24 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_24" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
      <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class="modal-body">
        <table class="table table-striped">
          <thead>
            <tr>
              <th colspan="1">Arm Group Type</th>
              <th colspan="1">Arm Group Description</th>
              <th colspan="1">Arm Group Intervention</th>
              <th colspan="1">Primary Outcome Measure</th>
              <th colspan="1">Primary Outcome Description</th>
              <th colspan="1">Primary Outcome Time Frame</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td>Experimental; Active Comparator</td>
              <td>Patients undergo radical-dose image guided radiation therapy daily for up to 10 days (within 2 weeks) while undergoing standard of care immunotherapy.|Patients who decline to undergo radiation therapy receive standard of care immunotherapy.</td>
              <td>Radiation: Image Guided Radiation Therapy; Other: Laboratory Biomarker Analysis; Biological: Immunotherapy (standard of care)</td>
              <td>Progression-free survival</td>
              <td>Defined as proportion of patients without Response Evaluation Criteria in Solid Tumors version 1.1 disease progression or death 24 weeks from date of study entry.</td>
              <td>At 24 weeks after study entry</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_25" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
      <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class="modal-body">
        <table class="table table-striped">
          <thead>
            <tr>
              <th colspan="1">Arm Group Type</th>
              <th colspan="1">Arm Group Description</th>
              <th colspan="1">Arm Group Intervention</th>
              <th colspan="1">Primary Outcome Measure</th>
              <th colspan="1">Primary Outcome Description</th>
              <th colspan="1">Primary Outcome Time Frame</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td>Experimental</td>
              <td>The dose exploration part of the study will estimate the MTD and/or the RP2D.|Participants with non-squamous non-small cell lung cancer (NSCLC) will be administered the RP2D identified from the dose exploration part of the study.|Participants with squamous NSCLC will be administered the RP2D identified from the dose exploration part of the study.</td>
              <td>Drug: AMG 160</td>
              <td>Number of Participants who Experience One or More Dose-limiting Toxicities (DLTs)|Number of Participants who Experience One or More Treatment-emergent Adverse Event (TEAE)|Number of Participants who Experience One or More Treatment-related Adverse Events|Number of Participants who Experience Clinically Significant Changes in Vital Signs|Number of Participants who Experience Clinically Significant Changes in Clinical Laboratory Tests</td>
              <td></td>
              <td>28 days; Up to 3 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_26" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
      <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class="modal-body">
        <table class="table table-striped">
          <thead>
            <tr>
              <th colspan="1">Arm Group Type</th>
              <th colspan="1">Arm Group Description</th>
              <th colspan="1">Arm Group Intervention</th>
              <th colspan="1">Primary Outcome Measure</th>
              <th colspan="1">Primary Outcome Description</th>
              <th colspan="1">Primary Outcome Time Frame</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td>Experimental</td>
              <td>The recommended dosage of lorlatinib is 100 mg orally once daily with or without food until disease progression unacceptable toxicity or participant refusal/lost to follow-up. About 100 participants will be enrolled in this study.</td>
              <td>Drug: Lorlatinib</td>
              <td>Incidence of Adverse events (AEs)</td>
              <td></td>
              <td>From the time of first dose (Day 1) to at most 35 days post last dosing date or the date of initiation of a new anticancer therapy</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_27" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
      <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class="modal-body">
        <table class="table table-striped">
          <thead>
            <tr>
              <th colspan="1">Arm Group Type</th>
              <th colspan="1">Arm Group Description</th>
              <th colspan="1">Arm Group Intervention</th>
              <th colspan="1">Primary Outcome Measure</th>
              <th colspan="1">Primary Outcome Description</th>
              <th colspan="1">Primary Outcome Time Frame</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td>Experimental</td>
              <td>Patients receive fludarabine IV on days -5 to -3 cyclophosphamide IV on days -5 to -3 and COH06 IV on days 0 7 14 and 21 in the absence of disease progression or unacceptable toxicity. Patients assigned to dose level 4 also receive atezolizumab IV over 60 minutes on days 0 14 28 and 42 in the absence of disease progression or unacceptable toxicity.</td>
              <td>Procedure: Biospecimen Collection; Biological: Antineoplastic Immune Cell; Drug: Cyclophosphamide; Drug: Fludarabine; Biological: Atezolizumab</td>
              <td>Incidence of adverse events - CTCAE|Incidence of adverse events - ASTCT|Dose limiting toxicities</td>
              <td>Will be assessed and graded according to the Common Terminology Criteria for Adverse Events (CTCAE) grading system: The National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events version 5.0 using data obtained at each clinical assessment.; Will be assessed and graded according to the American Society for Transplantation and Cellular Therapy (ASTCT) Consensus Grading system: The ASTCT grading for Cytokine Release Syndrome (CRS) and Neurotoxicity associated with Immune Effector Cells using data obtained at each clinical assessment.</td>
              <td>Up to 2 years; Within 28 days of the first COH06 infusion</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_28" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
      <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class="modal-body">
        <table class="table table-striped">
          <thead>
            <tr>
              <th colspan="1">Arm Group Type</th>
              <th colspan="1">Arm Group Description</th>
              <th colspan="1">Arm Group Intervention</th>
              <th colspan="1">Primary Outcome Measure</th>
              <th colspan="1">Primary Outcome Description</th>
              <th colspan="1">Primary Outcome Time Frame</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td>Experimental; Active Comparator</td>
              <td>Participants will receive amivantamab 1050 milligram (mg) intravenously (IV) for body weight less than () 80 kilogram (kg) and 1400 mg for body weight greater than or equal to (=) 80 kg in 28-day cycles: once weekly in Cycle 1 (with a split dose on Days 1-2) and then every 2 weeks in subsequent cycles. Lazertinib will be administered 240 mg (80*3) orally once daily.|Participants will receive osimertinib 80 mg orally once daily plus matching placebo of lazertinib 240 mg (80*3) orally once daily.|Participants will receive lazertinib 240 mg (80*3) orally once daily plus matching placebo of osimertinib 80 mg orally once daily.</td>
              <td>Drug: Placebo; Drug: Amivantamab; Drug: Osimertinib; Drug: Lazertinib</td>
              <td>Progression-Free Survival (PFS) According to RECIST v1.1 by Blinded Independent Central Review (BICR)</td>
              <td>PFS is defined as the time from randomization until the date of objective disease progression or death whichever occurred first based on BICR using response evaluation criteria in solid tumors (RECIST) v1.1.</td>
              <td>Up to approximately 42 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_29" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
      <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class="modal-body">
        <table class="table table-striped">
          <thead>
            <tr>
              <th colspan="1">Arm Group Type</th>
              <th colspan="1">Arm Group Description</th>
              <th colspan="1">Arm Group Intervention</th>
              <th colspan="1">Primary Outcome Measure</th>
              <th colspan="1">Primary Outcome Description</th>
              <th colspan="1">Primary Outcome Time Frame</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td>Experimental; Placebo Comparator</td>
              <td>All randomized patients will receive osimertinib 80 mg QD with pemetrexed (500 mg/m^2) (with pre-treatment) plus either cisplatin (75 mg/m^2) or carboplatin ([AUC] 5) both administered on Day 1 of 21-day cycles for 4 cycles followed by osimertinib 80 mg QD plus pemetrexed maintenance (500 mg/m^2) on Day 1 of 21-day cycles|All randomized patients will receive placebo QD with pemetrexed (500 mg/m^2) (with pre-treatment) plus either cisplatin (75 mg/m^2) or carboplatin (AUC5) both administered on Day 1 of 21-day cycles for 4 cycles followed by placebo QD plus pemetrexed maintenance (500 mg/m^2) on Day 1 of 21-day cycles</td>
              <td>Drug: Osimertinib (AZD9291) pemetrexed cisplatin or carboplatin; Drug: Placebo for osimertinib (AZD9291) pemetrexed cisplatin or carboplatin</td>
              <td>Progression free survival (PFS): time from randomization until progression (intracranial or extracranial whichever occurs first) per RECIST 1.1 (for extracranial progression) and CNS RECIST 1.1 (for intracranial progression)</td>
              <td>To compare the efficacy of chemotherapy plus osimertinib treatment relative to chemotherapy plus placebo based on PFS</td>
              <td>At Screeningevery 6 weeks for the first 13 cycles (each cycle is 21 days)then every 12 weeks relative to randomizationand upto intracranial or extracranial disease progression or end of survival follow-upwhichever comes first (approximately 3 years)</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_30" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
      <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class="modal-body">
        <table class="table table-striped">
          <thead>
            <tr>
              <th colspan="1">Arm Group Type</th>
              <th colspan="1">Arm Group Description</th>
              <th colspan="1">Arm Group Intervention</th>
              <th colspan="1">Primary Outcome Measure</th>
              <th colspan="1">Primary Outcome Description</th>
              <th colspan="1">Primary Outcome Time Frame</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td>Experimental</td>
              <td>Patients receive brigatinib PO QD on days 1-28. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo LCT for up to 3 weeks in the absence of disease progression or unacceptable toxicity. Within 7 days after completion of LCT patients receive brigatinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.</td>
              <td>Drug: Brigatinib; Procedure: Local Consolidation Therapy</td>
              <td>Incidence of adverse events</td>
              <td>Toxicity data will be summarized using frequency tables. Associations between the types and severity of toxicity and treatment will be evaluated as well.</td>
              <td>Up to 2 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_31" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
      <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class="modal-body">
        <table class="table table-striped">
          <thead>
            <tr>
              <th colspan="1">Arm Group Type</th>
              <th colspan="1">Arm Group Description</th>
              <th colspan="1">Arm Group Intervention</th>
              <th colspan="1">Primary Outcome Measure</th>
              <th colspan="1">Primary Outcome Description</th>
              <th colspan="1">Primary Outcome Time Frame</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td>Experimental</td>
              <td>Patients receive poziotinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.</td>
              <td>Drug: Poziotinib</td>
              <td>Objective response rate a in patients with estimated glomerular filtration rate (EGFR) exon 20 mutant non-small Cell Lung Cancer (NSCLC) (Cohort 1)|Objective response rate a in patients with human epidermal growth factor receptor 2 (HER2) exon 20 mutant non-small Cell Lung Cancer (NSCLC) (Cohort 2)</td>
              <td>According to Response Evaluation Criteria in Solid Tumors 1.1 criteria.</td>
              <td>Up to 4 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_32" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
      <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class="modal-body">
        <table class="table table-striped">
          <thead>
            <tr>
              <th colspan="1">Arm Group Type</th>
              <th colspan="1">Arm Group Description</th>
              <th colspan="1">Arm Group Intervention</th>
              <th colspan="1">Primary Outcome Measure</th>
              <th colspan="1">Primary Outcome Description</th>
              <th colspan="1">Primary Outcome Time Frame</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td>Experimental; Placebo Comparator</td>
              <td>Intravenous administration of Durvalumab|Intravenous administration of placebo</td>
              <td>Drug: Durvalumab; Other: Placebo</td>
              <td>DFS in PD-L1 TC√¢‚Ä∞¬•1% (using Investigator assessments according to RECIST 1.1)</td>
              <td>To assess the efficacy of durvalumab compared to placebo as measured by DFS in the PD-L1 TC√¢‚Ä∞¬•1% analysis set</td>
              <td>Approximately 5 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_33" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
      <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class="modal-body">
        <table class="table table-striped">
          <thead>
            <tr>
              <th colspan="1">Arm Group Type</th>
              <th colspan="1">Arm Group Description</th>
              <th colspan="1">Arm Group Intervention</th>
              <th colspan="1">Primary Outcome Measure</th>
              <th colspan="1">Primary Outcome Description</th>
              <th colspan="1">Primary Outcome Time Frame</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td>Experimental; Placebo Comparator</td>
              <td>Intravenous administration of Experimental and Standard of Care Therapy|Intravenous administration of Placebo and Standard of Care Therapy</td>
              <td>Other: Placebo + SoC chemotherapy; Drug: Durvalumab + SoC chemotherapy</td>
              <td>Disease free survival (DFS) in MRD+ analysis set (using Investigator assessments according to RECIST 1.1)</td>
              <td>To assess the efficacy of durvalumab + SoC chemotherapy compared to placebo + SoC chemotherapy as measured by DFS in MRD+ patients</td>
              <td>approximately 4 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_34" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
      <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class="modal-body">
        <table class="table table-striped">
          <thead>
            <tr>
              <th colspan="1">Arm Group Type</th>
              <th colspan="1">Arm Group Description</th>
              <th colspan="1">Arm Group Intervention</th>
              <th colspan="1">Primary Outcome Measure</th>
              <th colspan="1">Primary Outcome Description</th>
              <th colspan="1">Primary Outcome Time Frame</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td>Experimental</td>
              <td>Participants will be treated with 12 √é¬ºg/kg of SOT101 on Day 1 Day 2 Day 8 and Day 9 of each 3-week cycle in combination with 200 mg pembrolizumab on Day 1 of each 3-week cycle.</td>
              <td>Drug: Pembrolizumab; Drug: SOT101</td>
              <td>Objective Response Rate (ORR) According to Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1)</td>
              <td></td>
              <td>Day 1 up to approximately 3 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_35" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
      <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class="modal-body">
        <table class="table table-striped">
          <thead>
            <tr>
              <th colspan="1">Arm Group Type</th>
              <th colspan="1">Arm Group Description</th>
              <th colspan="1">Arm Group Intervention</th>
              <th colspan="1">Primary Outcome Measure</th>
              <th colspan="1">Primary Outcome Description</th>
              <th colspan="1">Primary Outcome Time Frame</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td>Experimental</td>
              <td>Single Agent NZV930|Combination of NZV930 with PDR001|Combination of NZV930 with NIR178|Combination of NZV930 with NIR178 and PDR001</td>
              <td>Other: PDR001; Drug: NIR178; Other: NZV930</td>
              <td>Number of participants with adverse events as a measure of safety and tolerability of the NZV930 in combination with PDR001 and/or NIR178</td>
              <td>Incidence and severity of AEs and SAEs incl. changes in laboratory parameters vital signs and ECGs Dose limiting toxicity in cycle 1 (28 days) for single agent NZV930 and NZV930 in combination with PDR001 and/or NIR178 during dose escalation phase only Tolerability: dose interruptions Tolerability: dose reductions Tolerability: dose intensity</td>
              <td>3 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_36" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
      <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class="modal-body">
        <table class="table table-striped">
          <thead>
            <tr>
              <th colspan="1">Arm Group Type</th>
              <th colspan="1">Arm Group Description</th>
              <th colspan="1">Arm Group Intervention</th>
              <th colspan="1">Primary Outcome Measure</th>
              <th colspan="1">Primary Outcome Description</th>
              <th colspan="1">Primary Outcome Time Frame</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td>Experimental</td>
              <td>6 escalating doses of hSTC810 will be administered to participants</td>
              <td>Biological: hSTC810</td>
              <td>Incidence of DLTs|Incidence of AEs SAEs and abnormalities in Lab</td>
              <td>Number and percentages of subjects with DLTs; Number and percentages of subjects with Adverse Event serious AEs and abnormalities in lab parameters</td>
              <td>4 weeks; from signing ICF to 90 days after last dose</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_37" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
      <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class="modal-body">
        <table class="table table-striped">
          <thead>
            <tr>
              <th colspan="1">Arm Group Type</th>
              <th colspan="1">Arm Group Description</th>
              <th colspan="1">Arm Group Intervention</th>
              <th colspan="1">Primary Outcome Measure</th>
              <th colspan="1">Primary Outcome Description</th>
              <th colspan="1">Primary Outcome Time Frame</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td>Experimental</td>
              <td>Drug: JTX-4014|Drug: JTX-4014||Drug: Vopratelimab Other Name: JTX-2011|Drug: JTX-4014||Drug: Vopratelimab Other Name: JTX-2011</td>
              <td>Drug: JTX-4014; Drug: Vopratelimab</td>
              <td>Change in measurable lesion size</td>
              <td>Mean percent change from baseline in all measurable lesions</td>
              <td>averaged over 9 and 18 weeks</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_38" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
      <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class="modal-body">
        <table class="table table-striped">
          <thead>
            <tr>
              <th colspan="1">Arm Group Type</th>
              <th colspan="1">Arm Group Description</th>
              <th colspan="1">Arm Group Intervention</th>
              <th colspan="1">Primary Outcome Measure</th>
              <th colspan="1">Primary Outcome Description</th>
              <th colspan="1">Primary Outcome Time Frame</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td>Experimental; Active Comparator</td>
              <td>Ceritinib patients were on continuous oral dosing of ceritinib 750 mg once daily in fasted state.|Chemotherapy patients (Induction per Investigator's choice) were on four 21-day cycles of Pemetrexed 500mg/m2 iv + Cisplatin 75 mg/m2 or Pemetrexed 500 mg/m2 iv + Carboplatin AUC 5-6 iv followed by Pemetrexed 500 mg/m2 every 21 days followed by Pemetrexed maintenance in non-progressors etc (other usual rule to stop treatment).</td>
              <td>Drug: Ceritinib; Drug: Cisplatin; Drug: Carboplatin; Drug: Pemetrexed</td>
              <td>Progression Free Survival (PFS) by Blinded Independent Review Committee (BIRC)</td>
              <td>PFS defined as time from date of randomization to date of first documented disease (as assessed by Blinded Independent Review Committee (BIRC) per RECIST 1.1) or date of death due to any cause</td>
              <td>from the date of randomization to the date of first radiologically documented disease progression or death due to any cause (assessed every 6 weeks up to approximately 34 months)</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_39" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
      <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class="modal-body">
        <table class="table table-striped">
          <thead>
            <tr>
              <th colspan="1">Arm Group Type</th>
              <th colspan="1">Arm Group Description</th>
              <th colspan="1">Arm Group Intervention</th>
              <th colspan="1">Primary Outcome Measure</th>
              <th colspan="1">Primary Outcome Description</th>
              <th colspan="1">Primary Outcome Time Frame</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td>Experimental</td>
              <td></td>
              <td>Drug: 3.Experimental: C (Part 2): Fluzoparib and SHR -1316 Expansion; Drug: 2.Experimental: B (Part 1): Fluzoparib and SHR -1316; Drug: 1.Experimental: A (Part 1): Fluzoparib and SHR -1316</td>
              <td>Part 1: 1.Number of Participants with AEs and SAEs|Part 1: 2. RP2D: Recommended dose for phase II study|Part 2: 1. ORR: Percentage of Participants With a CR or PR</td>
              <td></td>
              <td>Up to approximately 24 months.</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_40" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
      <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class="modal-body">
        <table class="table table-striped">
          <thead>
            <tr>
              <th colspan="1">Arm Group Type</th>
              <th colspan="1">Arm Group Description</th>
              <th colspan="1">Arm Group Intervention</th>
              <th colspan="1">Primary Outcome Measure</th>
              <th colspan="1">Primary Outcome Description</th>
              <th colspan="1">Primary Outcome Time Frame</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td>Experimental</td>
              <td>Participants from outside of Korea with progressive disease and on prior epidermal growth factor receptor (EGFR) Tyrosine kinase inhibitor (TKI) therapy will receive recommended phase 2 doses based on safety tolerability efficacy and pharmacokinetics (PK) of Lazertinib.</td>
              <td>Drug: Lazertinib</td>
              <td>Part D: Number of Participants with Adverse Event as a Measure of Safety and Tolerability|Part D: Plasma Concentration of Lazertinib After Administration of Single Dose (SD)|Part D: Plasma Concentration of Lazertinib After Administration of Multiple Dose (MD)</td>
              <td>Plasma Concentration of Lazertinib after administration of multiple dose will be evaluated.; An adverse event is any untoward medical event that occurs in a participants administered an investigational product and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.; Plasma Concentration of Lazertinib after administration of single dose will be evaluated.</td>
              <td>Up to 2 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_41" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
      <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class="modal-body">
        <table class="table table-striped">
          <thead>
            <tr>
              <th colspan="1">Arm Group Type</th>
              <th colspan="1">Arm Group Description</th>
              <th colspan="1">Arm Group Intervention</th>
              <th colspan="1">Primary Outcome Measure</th>
              <th colspan="1">Primary Outcome Description</th>
              <th colspan="1">Primary Outcome Time Frame</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td>Experimental</td>
              <td>Participants receive panitumumab- IRDye800 IV over 60 minutes on day 0 and then undergo NIR and surgery within 1-5 days.</td>
              <td>Other: Pharmacokinetic Study; Procedure: Therapeutic Conventional Surgery; Drug: Panitumumab-IRDye800; Procedure: Near-Infrared Fluorescence Imaging</td>
              <td>Tumor to background ratio (TBR) measured in ex vivo tissues</td>
              <td>The TBR is defined as the near-infrared fluorescence signal of tumor or lymph node tissue compared to normal adjacent tissue measured in ex vivo tissues. Outcomes will be reported as the TBR (mean) and standard deviation for each dose group and timing group (1-2 days or 3-5 days prior to surgery).</td>
              <td>Up to 1 year</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_42" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
      <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class="modal-body">
        <table class="table table-striped">
          <thead>
            <tr>
              <th colspan="1">Arm Group Type</th>
              <th colspan="1">Arm Group Description</th>
              <th colspan="1">Arm Group Intervention</th>
              <th colspan="1">Primary Outcome Measure</th>
              <th colspan="1">Primary Outcome Description</th>
              <th colspan="1">Primary Outcome Time Frame</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td>Experimental</td>
              <td>Durvalumab 1500 mg via IV infusion will be concurrently administered with first-line chemotherapy (EP) on an every 3 week (q3w) schedule for 4 to 6 cycles and will continue to be administered post-chemotherapy on an every 4 week (q4w) schedule until confirmed progressive disease (PD) or unacceptable toxicity.</td>
              <td>Drug: Durvalumab; Drug: Cisplatin; Drug: Etoposide; Drug: Carboplatin</td>
              <td>Incidence of grade √¢‚Ä∞¬• 3 Adverse Events (AE)|Incidence of Immune Mediated Adverse Events (imAE).</td>
              <td></td>
              <td>Up to 18 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_43" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
      <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class="modal-body">
        <table class="table table-striped">
          <thead>
            <tr>
              <th colspan="1">Arm Group Type</th>
              <th colspan="1">Arm Group Description</th>
              <th colspan="1">Arm Group Intervention</th>
              <th colspan="1">Primary Outcome Measure</th>
              <th colspan="1">Primary Outcome Description</th>
              <th colspan="1">Primary Outcome Time Frame</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td>Experimental</td>
              <td>Patients will receive afatinib once daily</td>
              <td>Drug: afatinib</td>
              <td>Adverse Events according to Common Terminology Criteria (CTCAE Version 3)</td>
              <td></td>
              <td>up to 24 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_44" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
      <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class="modal-body">
        <table class="table table-striped">
          <thead>
            <tr>
              <th colspan="1">Arm Group Type</th>
              <th colspan="1">Arm Group Description</th>
              <th colspan="1">Arm Group Intervention</th>
              <th colspan="1">Primary Outcome Measure</th>
              <th colspan="1">Primary Outcome Description</th>
              <th colspan="1">Primary Outcome Time Frame</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td>Experimental</td>
              <td>This will be a single-institution open label two-stage single agent trial of cabozantinib in patients with advanced NSCLCs.atients in GROUP A will have tumors with a RET fusion. Patients in GROUP B will have tumors with an NTRK fusion or MET or AXL overexpression amplication or mutatation. Patients in GROUP C will have tumors with a ROS1 fusion. Patients in GROUP D will have tumors with a RET fusion and have progressed on a selective RET TKI.</td>
              <td>Drug: Cabozantinib</td>
              <td>objective response rate (ORR) (Group A)|objective response rate (ORR) (Group B)</td>
              <td>by RECIST v1.1 criteria to cabozantinib in patients with advanced NSCLC who have tested positive for RET Fusion; by RECIST v1.1 criteria to cabozantinib in patients with advanced NSCLC whose tumors test positive for a ROS1 or NTRK fusion or MET or AXL overexpression amplification or mutation.</td>
              <td>12 weeks</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_45" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
      <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class="modal-body">
        <table class="table table-striped">
          <thead>
            <tr>
              <th colspan="1">Arm Group Type</th>
              <th colspan="1">Arm Group Description</th>
              <th colspan="1">Arm Group Intervention</th>
              <th colspan="1">Primary Outcome Measure</th>
              <th colspan="1">Primary Outcome Description</th>
              <th colspan="1">Primary Outcome Time Frame</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td>Experimental; Active Comparator</td>
              <td>Patients receive infliximab IV over 1 hour once at week 0 2 6 for a total of 3 doses in the absence of disease progression or unacceptable toxicity.|Patients receive vedolizumab IV over 1 hour at week 0 2 6 for a total of 3 doses in the absence of disease progression or unacceptable toxicity.</td>
              <td>Biological: Vedolizumab; Biological: Infliximab</td>
              <td>Clinical remission/response rate of immune-mediated colitis (IMC)|Treatment-related adverse events</td>
              <td>The difference of the remission rate between standard of care (infliximab + corticosteroid) and the treatment with vedolizumab + corticosteroid will be calculated along with the 95% confidence interval.; Will follow standard reporting guidelines for adverse events. Safety data will be summarized by category severity and frequency.</td>
              <td>Within 3 months after initiation of infliximab or vedolizumab; At 2 weeks after initiation of infliximab or vedolizumab with corticosteroid taper</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_46" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
      <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class="modal-body">
        <table class="table table-striped">
          <thead>
            <tr>
              <th colspan="1">Arm Group Type</th>
              <th colspan="1">Arm Group Description</th>
              <th colspan="1">Arm Group Intervention</th>
              <th colspan="1">Primary Outcome Measure</th>
              <th colspan="1">Primary Outcome Description</th>
              <th colspan="1">Primary Outcome Time Frame</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td>Experimental</td>
              <td>All participants enrolled in the dose escalation part|All participants enrolled in the dose expansion part</td>
              <td>Drug: Datopotamab Deruxtecan (Dato-DXd)</td>
              <td>Number of participants with dose-limiting toxicities|Number of participants with adverse events (AEs)</td>
              <td>Dose-limiting toxicities are defined as side effects of a drug or other treatment that are serious enough to prevent an increase in dose or level of that treatment.</td>
              <td>When all participants have either discontinued the study or the last participant enrolled in the study has completed at least 6 months of follow up (approximately 4 years); Within 8 cycles (each cycle is 21 days)</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_47" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
      <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class="modal-body">
        <table class="table table-striped">
          <thead>
            <tr>
              <th colspan="1">Arm Group Type</th>
              <th colspan="1">Arm Group Description</th>
              <th colspan="1">Arm Group Intervention</th>
              <th colspan="1">Primary Outcome Measure</th>
              <th colspan="1">Primary Outcome Description</th>
              <th colspan="1">Primary Outcome Time Frame</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td>Experimental</td>
              <td>Participants receive porfimer sodium IV over 3-5 minutes and receive IO-PDT via a light dosimetry system 24-48 hours later.</td>
              <td>Procedure: Photodynamic Therapy; Device: Light Dosimetry for Intranoperative Therapy; Drug: Porfimer Sodium</td>
              <td>Incidence of adverse events per National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0</td>
              <td>The frequency of toxicities will be tabulated by grade across all dose levels and cycles. All subjects who receive any study treatment will be considered evaluable for toxicity.</td>
              <td>Up to 30 days</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_48" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
      <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class="modal-body">
        <table class="table table-striped">
          <thead>
            <tr>
              <th colspan="1">Arm Group Type</th>
              <th colspan="1">Arm Group Description</th>
              <th colspan="1">Arm Group Intervention</th>
              <th colspan="1">Primary Outcome Measure</th>
              <th colspan="1">Primary Outcome Description</th>
              <th colspan="1">Primary Outcome Time Frame</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td>Experimental</td>
              <td>Patients will receive CT053PTSA and gefitinib over a 28-day cycle until progressive disease intolerable toxicity or subject's withdrawal from treatment.||CT053PTSA will be administered daily at a dose of 30 mg/40mg/60mg orally .||Gefitinib will be administered daily at a dose of 250 mg orally .</td>
              <td>Drug: Gefitinib; Drug: CT053PTSA</td>
              <td>Part 1√Ø¬ºÀÜdose-escalation part√Ø¬º‚Ä∞: Maximum Tolerated Dose (MTD)|Part 2√Ø¬ºÀÜexpansion part√Ø¬º‚Ä∞: Overall Response Rate</td>
              <td>Overall response rate (ORR) defined as a partial response (PR) or complete response (CR) occurring at any point post-treatment according to Response Evaluation Criteria in Solid Tumors as assessed by RECIST v1.1; The maximum tolerated dose (MTD) of the CT053PTSA and gefitinib combination will be determined according to incidence of dose-limiting toxicity (DLT) assessed by NCI CTCAE v4.03</td>
              <td>up to approximately 36 months; Cycle 1 Day 1 to Cycle 1 Day 28</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_49" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
      <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class="modal-body">
        <table class="table table-striped">
          <thead>
            <tr>
              <th colspan="1">Arm Group Type</th>
              <th colspan="1">Arm Group Description</th>
              <th colspan="1">Arm Group Intervention</th>
              <th colspan="1">Primary Outcome Measure</th>
              <th colspan="1">Primary Outcome Description</th>
              <th colspan="1">Primary Outcome Time Frame</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td>Experimental</td>
              <td>Beginning 7-14 days prior to start of pembrolizumab nivolumab or atezolizumab patients receive nelfinavir mesylate PO BID on days 1-7 or 1-14 (dependent upon when treatment is started) up to 11-12 weeks. Patients also receive pembrolizumab nivolumab or atezolizumab IV over 30-60 minutes on day 1. Cycles repeat every 21-28 days in the absence of disease progression or unacceptable toxicity. Patients then undergo hypofractionated radiation therapy over 3-14 days starting after cycle 1 and before cycle 3 of pembrolizumab nivolumab or atezolizumab. The study will exclude irradiation of liver metastases as an added precaution.</td>
              <td>Drug: Atezolizumab; Radiation: Hypofractionated Radiation Therapy; Other: Laboratory Biomarker Analysis; Drug: Nelfinavir Mesylate; Biological: Pembrolizumab; Biological: Nivolumab</td>
              <td>Response Rate</td>
              <td>"Will be determined by immune-related Response Evaluation Criteria in Solid Tumor 1.1. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by CT Scan: Complete Response (CR) Disappearance of all target lesions; Partial Response (PR) =30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR."""</td>
              <td>Up to 6 months after initiating treatment</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_50" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
      <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class="modal-body">
        <table class="table table-striped">
          <thead>
            <tr>
              <th colspan="1">Arm Group Type</th>
              <th colspan="1">Arm Group Description</th>
              <th colspan="1">Arm Group Intervention</th>
              <th colspan="1">Primary Outcome Measure</th>
              <th colspan="1">Primary Outcome Description</th>
              <th colspan="1">Primary Outcome Time Frame</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td>Experimental</td>
              <td>Lympho-conditioning agents followed by ACE1702 (anti-HER2 oNK cells) will be administered to patients with advanced or metastatic HER2-expressing solid tumors. HER2 expressing is defined has having HER2 immunohistochemistry (IHC) 2+ or above.||Dose Level: 1 Planned number of subjects: 1 to 6|Lympho-conditioning agents followed by ACE1702 (anti-HER2 oNK cells) will be administered to patients with advanced or metastatic HER2-expressing solid tumors. HER2 expressing is defined has having HER2 IHC 2+ or above.||Dose Level: 2 Planned number of subjects: 1 to 6|Lympho-conditioning agents followed by ACE1702 (anti-HER2 oNK cells) will be administered to patients with advanced or metastatic HER2-expressing solid tumors. HER2 expressing is defined has having HER2 IHC 2+ or above.||Dose Level: 3 Planned number of subjects: 3 to 6|Lympho-conditioning agents followed by ACE1702 (anti-HER2 oNK cells) will be administered to patients with advanced or metastatic HER2-expressing solid tumors. HER2 expressing is defined has having HER2 IHC 2+ or above.||Dose Level: 4 Planned number of subjects: 3 to 6|Lympho-conditioning agents followed by ACE1702 (anti-HER2 oNK cells) will be administered to patients with advanced or metastatic HER2-expressing solid tumors. HER2 expressing is defined has having HER2 IHC 2+ or above.||Dose Level: 5 Planned number of subjects: 3 to 6|Lympho-conditioning agents followed by ACE1702 (anti-HER2 oNK cells) will be administered to patients with advanced or metastatic HER2-expressing solid tumors. HER2 expressing is defined has having HER2 IHC 2+ or above.||Dose Level: 6 Planned number of subjects: 3 to 6</td>
              <td>Drug: ACE1702; Drug: Fludarabine; Drug: Cyclophosphamide</td>
              <td>Adverse events including Dose Limiting Toxicities (DLTs) and Serious Adverse Events (SAEs)|Phase Ib/II starting dose for ACE1702</td>
              <td>Number of subjects experiencing adverse events and the frequency and severity of adverse events.; The recommended phase Ib/II starting dose based on MTD. If MTD is not reached then the recommended phase Ib/II dose will be determined based on the MAD safety data and pharmacodynamics data.; Endpoint for determining the Maximum Tolerated Dose (MTD). If MTD is not identified the highest dose administered becomes the Maximum Administered Dose (MAD).</td>
              <td>Through study completion up to 1 year; Day 7 through Day 28 / Day 4 through Day 25</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_51" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
      <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class="modal-body">
        <table class="table table-striped">
          <thead>
            <tr>
              <th colspan="1">Arm Group Type</th>
              <th colspan="1">Arm Group Description</th>
              <th colspan="1">Arm Group Intervention</th>
              <th colspan="1">Primary Outcome Measure</th>
              <th colspan="1">Primary Outcome Description</th>
              <th colspan="1">Primary Outcome Time Frame</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td>Experimental</td>
              <td></td>
              <td>Biological: nivolumab; Biological: cetuximab; Biological: BMS-986315</td>
              <td>Incidence of adverse events (AEs)|Incidence of serious adverse events (SAEs)|Incidence of adverse events (AEs) meeting protocol-defined DLT (dose-limiting toxicity) criteria|Incidence of adverse events (AEs) leading to discontinuation|Number of deaths</td>
              <td></td>
              <td>Up to 119 weeks</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_52" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
      <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class="modal-body">
        <table class="table table-striped">
          <thead>
            <tr>
              <th colspan="1">Arm Group Type</th>
              <th colspan="1">Arm Group Description</th>
              <th colspan="1">Arm Group Intervention</th>
              <th colspan="1">Primary Outcome Measure</th>
              <th colspan="1">Primary Outcome Description</th>
              <th colspan="1">Primary Outcome Time Frame</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td>Experimental</td>
              <td>Cohort 1: Patients with Non-Small Cell Lung Cancer with squamous cell or adenocarcinoma histology who have not been treated with a PD-1 or PD-L-1 blocking antibody (entinostat + pembrolizumab)|Cohort 2: Patients with NSCLC (any histology) who have previously been treated with and unequivocally progressed on either a PD-1 or PD-L1-blocking antibody (entinostat + pembrolizumab)|Cohort 3: Patients with melanoma who have previously been treated with and unequivocally progressed on either a PD-1 or PD-L1-blocking antibody (entinostat + pembrolizumab)|Cohort 4: Patients with CRC (mismatch repair-proficient) who have not been previously treated with a PD-1 or PD-L1 blocking antibody</td>
              <td>Drug: pembrolizumab; Drug: entinostat</td>
              <td>Number of Participants taking 3mg entinostat weekly with Adverse Events as a Measure of Safety and Tolerability|Number of Participants taking 5mg entinostat weekly with Adverse Events as a Measure of Safety and Tolerability|Overall Response Rate using irRECIST for Phase 2 Dose and Schedule for Cohort 1 Stage 1 (NSCLC)|Overall Response Rate using irRECIST for Phase 2 Dose and Schedule for Cohort 2 Stage 1 (NSCLC pre-treated)|Overall Response Rate using irRECIST for Phase 2 Dose and Schedule for Cohort 3 Stage 1 (Melanoma pre-treated)|Overall Response Rate using irRECIST for Phase 2 Dose and Schedule for Cohort 1 Stage 2 (NSCLC)|Overall Response Rate using irRECIST for Phase 2 Dose and Schedule for Cohort 2 Stage 2 (NSCLC pre-treated)|Overall Response Rate using irRECIST for Phase 2 Dose and Schedule for Cohort 3 Stage 2 (Melanoma pre-treated)</td>
              <td>Ph 1 Dose Escalation - All patients within each dose escalation cohort are to complete C1 have safety assessments performed through C2D1 and be assessed for DLT before enrollment of the next cohort may commence.; - Cohort 2 Stage 1: If enough patients achieve an objective response then enrollment will continue into the second stage.; - Cohort 1 Stage 1: If enough patients achieve an objective response (CR or PR) enrollment will continue into the second stage.; Measured by Overall Response Rate using irRECIST.; - Cohort 2 Stage 2: IIf enough patients achieve a CR or PR than the true ORR for the combination therapy.; - Cohort 3 Stage 1: If enough patients achieve an objective response then enrollment will continue into the second stage.; Cohort 1 Stage 2: If enough patients achieve a CR or PR than the true ORR for the combination therapy.; - Cohort 3 Stage 2: If enough patients achieve a CR or PR than the true ORR for the combination therapy.</td>
              <td>In approximately 6-8 months after 3-6 patients have enrolled and been on study for 1 cycle; In approximately 2 years; In approximately 1 year; In approximately 3-4 months after 3-6 patients have enrolled and been on study for 1 cycle</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>
<!-- ############################### -->
<!-- ############################### -->
<!-- ########### NEW LC ############ -->
<!-- ############################### -->
<!-- ############################### -->

<br>
<h2 id="new_lc">New Trials</h2>
<h4><a href="#home">Home</a></h4>
<table border="1" summary="Long-term goals table" width="100%" cellspacing="0" cellpadding="0">
  <thead>
    <tr>
      <th>
        <h3>Condition</h3>
      </th>
      <th>
        <h3>Sponsor</h3>
      </th>
      <th>
        <h3>Phase</h3>
      </th>
      <th>
        <h3>Intervention</h3>
      </th>
      <th>
        <h3>Trial ID</h3>
      </th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Advanced Lung Cancer patients who failed PD-1/L1 Inhibitor</td>
      <td>Mabwell (Shanghai) Bioscience Co. Ltd.</td>
      <td>Phase 2</td>
      <td><button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_1">6MW3211</button></td>
      <td>NCT05431569</td>
    </tr>
    <tr>
      <td>Adult patients with metastatic NSCLC with liver metastases</td>
      <td>VA Ann Arbor Healthcare System</td>
      <td>Phase 1</td>
      <td><button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_2">Liver SBRT; Pembrolizumab</button></td>
      <td>NCT05430009</td>
    </tr>
    <tr>
      <td>EGFR mutated stage IIIA-IIIB resectable NSCLC</td>
      <td>Tang-Du Hospital</td>
      <td>Phase 2</td>
      <td><button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_3">Furmonertinib+cisplating/pemetrexed</button></td>
      <td>NCT05430802</td>
    </tr>
    <tr>
      <td>Treatment naive EGFR wild-type locally advanced metastatic or recurrent non-squamous non-small cell lung cancer (ns-NSCLC) patients</td>
      <td>TOT Biopharm Co. Ltd.</td>
      <td>Phase 3</td>
      <td><button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_4">TAB008; Bevacizumab</button></td>
      <td>NCT05427305</td>
    </tr>
    <tr>
      <td>EGFRm+ advanced NSCLC</td>
      <td>Jiangsu Hansoh Pharmaceutical Co. Ltd.</td>
      <td>Phase 1</td>
      <td><button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_5">HS-10241</button></td>
      <td>NCT05430386</td>
    </tr>
    <tr>
      <td>Resectable Squamous Cell NSCLC</td>
      <td>Second Affiliated Hospital School of Medicine Zhejiang University</td>
      <td>Phase 3</td>
      <td><button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_6">Sintilimab; Carboplatin; Albumin-Bound Paclitaxel</button></td>
      <td>NCT05429463</td>
    </tr>
    <tr>
      <td>G12C Non-Small Cell Lung Cancer (NSCLC) who have been exposed to prior G12C inhibitor and experienced progressive disease</td>
      <td>Verastem Inc.</td>
      <td>Phase 1|Phase 2</td>
      <td><button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_7">VS-6766 and adagrasib</button></td>
      <td>NCT05375994</td>
    </tr>
    <tr>
      <td>In Escalation: All Patients With Solid Tumors and Lymphoma; In Expansion: Melanoma Non-small Cell Lung Cancer</td>
      <td>Novartis Pharmaceuticals</td>
      <td>Phase 1</td>
      <td><button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_8">NIZ985; Spartalizumab; Tislelizumab</button></td>
      <td>NCT04261439</td>
    </tr>
    <tr>
      <td>Solid tumours</td>
      <td>Jules Bordet Institute</td>
      <td>Phase 2</td>
      <td><button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_9">Checkpoint Blockade Immune</button></td>
      <td>NCT05429866</td>
    </tr>
    <tr>
      <td>Metastatic CCNE1 amplified and TP53 mutant solid tumors</td>
      <td>M.D. Anderson Cancer Center</td>
      <td>Phase 1</td>
      <td><button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_10">ZN-c3; Bevacizumab; Pembrolizumab</button></td>
      <td>NCT05431582</td>
    </tr>
    <tr>
      <td>Malignant pleural mesothelioma</td>
      <td>Oncotelic Inc.</td>
      <td>Phase 2</td>
      <td><button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_11">OT-101</button></td>
      <td>NCT05425576</td>
    </tr>
    <tr>
      <td>Malignancies Including Melanoma; Kidney; Lung; Colorectal; Prostate; Neuroendocrine Tumor</td>
      <td>Sichuan Huiyang Life Science and Technology Corporation</td>
      <td>Phase 1</td>
      <td><button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_12">rSIFN-co</button></td>
      <td>NCT02464007</td>
    </tr>
  </tbody>
</table>
<!-- THE MODAL -->
<div class="modal fade" id="modal_1" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
      <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class="modal-body">
        <table class="table table-striped">
          <thead>
            <tr>
              <th colspan="1">Arm Group Type</th>
              <th colspan="1">Arm Group Description</th>
              <th colspan="1">Arm Group Intervention</th>
              <th colspan="1">Primary Outcome Measure</th>
              <th colspan="1">Primary Outcome Description</th>
              <th colspan="1">Primary Outcome Time Frame</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td>Experimental</td>
              <td>6MW3211injection30mg/kgQ2W</td>
              <td>Drug: 6MW3211</td>
              <td>ORR</td>
              <td>The percentage of (PR+CR) after treatment to the total number of cases was calculated</td>
              <td>up to 24mouths or intolerable toxicity disease progression or death patient withdrawal of informed consent withdrawal from the study and so on</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_2" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
      <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class="modal-body">
        <table class="table table-striped">
          <thead>
            <tr>
              <th colspan="1">Arm Group Type</th>
              <th colspan="1">Arm Group Description</th>
              <th colspan="1">Arm Group Intervention</th>
              <th colspan="1">Primary Outcome Measure</th>
              <th colspan="1">Primary Outcome Description</th>
              <th colspan="1">Primary Outcome Time Frame</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td>Experimental</td>
              <td>This is an open-label single-arm single center clinical trial to evaluate the feasibility of liver SBRT (up to 4 metastases) during the first cycle of physician's choice ICI for NSCLC.</td>
              <td>Radiation: Liver SBRT; Drug: Pembrolizumab</td>
              <td>Percentage of patients who receive all fractions of radiotherapy as planned</td>
              <td>Feasibility determination. Analyzed with descriptive statistics.</td>
              <td>Up to 0.5 years after start of study treatment</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_3" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
      <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class="modal-body">
        <table class="table table-striped">
          <thead>
            <tr>
              <th colspan="1">Arm Group Type</th>
              <th colspan="1">Arm Group Description</th>
              <th colspan="1">Arm Group Intervention</th>
              <th colspan="1">Primary Outcome Measure</th>
              <th colspan="1">Primary Outcome Description</th>
              <th colspan="1">Primary Outcome Time Frame</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td>Experimental</td>
              <td>furmonertinib 80mg/d for 9 weeks and cisplatin 75mg/m2 d1 iv + pemetrexed 500mg/m2 d1 iv at 21 day cycles for 3 cycles</td>
              <td>Drug: Furmonertinib+cisplating/pemetrexed</td>
              <td>Objective response rate</td>
              <td>The proportion of patients with complete response or partial response</td>
              <td>Approximately 9 weeks following the first dose of study drug</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_4" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
      <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class="modal-body">
        <table class="table table-striped">
          <thead>
            <tr>
              <th colspan="1">Arm Group Type</th>
              <th colspan="1">Arm Group Description</th>
              <th colspan="1">Arm Group Intervention</th>
              <th colspan="1">Primary Outcome Measure</th>
              <th colspan="1">Primary Outcome Description</th>
              <th colspan="1">Primary Outcome Time Frame</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td>Experimental; Active Comparator</td>
              <td>Eligible patients received TAB008 15 mg/kg every three weeks for 6 cycles then 7.5mg/kg until disease progression intolerable toxicity withdrawal of consent lost to follow up or death.|Eligible patients received bevacizumab-EU 15 mg/kg every three weeks for 6 cycles then 7.5mg/kg until disease progression intolerable toxicity withdrawal of consent lost to follow up or death.</td>
              <td>Drug: Bevacizumab; Drug: TAB008</td>
              <td>ORR</td>
              <td>The primary endpoint is overall response rate (ORR) within the first 6 cycles of treatment.ORR includes Complete Response Rate and Partial Response Rate.ORR will be independently evaluated by the independent radiology review committee (IRRC).</td>
              <td>at the end of cycle 6 (each cycle is 21 days).</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_5" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
      <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class="modal-body">
        <table class="table table-striped">
          <thead>
            <tr>
              <th colspan="1">Arm Group Type</th>
              <th colspan="1">Arm Group Description</th>
              <th colspan="1">Arm Group Intervention</th>
              <th colspan="1">Primary Outcome Measure</th>
              <th colspan="1">Primary Outcome Description</th>
              <th colspan="1">Primary Outcome Time Frame</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td>Experimental</td>
              <td>HS-10241 in combination with Almonertinib</td>
              <td>Drug: HS-10241</td>
              <td>Part1-To determine the maximum tolerated dose (MTD)|Part2- Objective response rate (ORR )</td>
              <td>ORR was defined as the percentage of patients with a complete response (CR) or partial response (PR) that was confirmed at a subsequent scan at least 4 weeks later as assessed according to RECIST version 1.1.; MTD was defined as the previous dose level at which 2 out of 3 patients or 2 out of 6 patients experienced a DLT.</td>
              <td>Up to day 28 from the first dose (4 weeks).; From first dose until disease progression or withdrawal from study assessed up to 24 months.</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_6" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
      <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class="modal-body">
        <table class="table table-striped">
          <thead>
            <tr>
              <th colspan="1">Arm Group Type</th>
              <th colspan="1">Arm Group Description</th>
              <th colspan="1">Arm Group Intervention</th>
              <th colspan="1">Primary Outcome Measure</th>
              <th colspan="1">Primary Outcome Description</th>
              <th colspan="1">Primary Outcome Time Frame</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td>Experimental</td>
              <td>Neoadjuvant: Prior to surgery participants receive up to 2 cycles (cycle length: 3 weeks) of sintilimab [200 mg intravenous (IV); given on cycle day 1] in combination with neoadjuvant chemotherapy consisting of albumin-bound paclitaxel [260 mg/m^2 IV; given on cycle day 1] and carboplatin [AUC 5- 6mg/mL/min IV; given on cycle day 1 ] .||Adjuvant: Followed by surgery within the 4th week after the second dose of sintilimab participants will receive 2 cycles of adjuvant chemotherapy with the original regimen and the researcher will decide whether to radiotherapy or not according to the clinical situation and pathological stage of the patient. The maintenance treatment of sintilimab [200 mg intravenous (IV); given on cycle day 1; cycle length: 3 weeks] may be selected upon subject request for up to 1 year.|Neoadjuvant: Prior to surgery participants receive up to 4 cycles (cycle length: 3 weeks) of sintilimab [200 mg intravenous (IV); given on cycle day 1] in combination with neoadjuvant chemotherapy consisting of albumin-bound paclitaxel [260 mg/m^2 IV; given on cycle day 1] and carboplatin [AUC 5- 6mg/mL/min IV; given on cycle day 1 ] .||Adjuvant: Followed by surgery within the 4th week after the second dose of sintilimab the researcher will decide whether to radiotherapy or not according to the clinical situation and pathological stage of the patient. The maintenance treatment of sintilimab [200 mg intravenous (IV); given on cycle day 1; cycle length: 3 weeks] may be selected upon subject request for up to 1 year.</td>
              <td>Drug: Albumin-Bound Paclitaxel; Biological: Sintilimab; Drug: Carboplatin</td>
              <td>Major pathological response rate (MPR)</td>
              <td>MPR rate is defined as the percentage of participants having √¢‚Ä∞¬§10% viable tumor cells in the pathological examination of resected specimens.</td>
              <td>At time of surgery</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_7" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
      <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class="modal-body">
        <table class="table table-striped">
          <thead>
            <tr>
              <th colspan="1">Arm Group Type</th>
              <th colspan="1">Arm Group Description</th>
              <th colspan="1">Arm Group Intervention</th>
              <th colspan="1">Primary Outcome Measure</th>
              <th colspan="1">Primary Outcome Description</th>
              <th colspan="1">Primary Outcome Time Frame</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td>Experimental</td>
              <td>To determine the recommended phase 2 dose (RP2D) for VS-6766 in combination with adagrasib in G12C inhibitor exposed patients|To determine the efficacy of the RP2D identified from Part A in G12C inhibitor exposed patients</td>
              <td>Drug: VS-6766 and adagrasib</td>
              <td>Part A: To determine RP2D for VS-6766 in combination with adagrasib|To determine the efficacy of the optimal regimen identified from Part A</td>
              <td>Assessment of Dose-limiting toxicities (DLTs); Confirmed overall response rate per RECIST 1.1</td>
              <td>From start of treatment to confirmation of RP2D; 28 days; From start of treatment to confirmation of response; 16 weeks</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_8" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
      <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class="modal-body">
        <table class="table table-striped">
          <thead>
            <tr>
              <th colspan="1">Arm Group Type</th>
              <th colspan="1">Arm Group Description</th>
              <th colspan="1">Arm Group Intervention</th>
              <th colspan="1">Primary Outcome Measure</th>
              <th colspan="1">Primary Outcome Description</th>
              <th colspan="1">Primary Outcome Time Frame</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td>Experimental</td>
              <td>Single agent arm. NIZ985 is administered as a single agent (subjects may be treated with the NIZ985-Spartalizumab combination after their first disease re-evaluation)|Combination arm. NIZ985 and Spartalizumab combination is administered starting at Cycle 1 Day 1 in dose escalation. NIZ985 and tislelizumab combination is administered starting at Cycle 1 Day 1 in dose expansion.</td>
              <td>Drug: Spartalizumab; Drug: Tislelizumab; Drug: NIZ985</td>
              <td>Incidence of Dose Limiting Toxcities (DLTs) in escalation and expansion|Number of patients with and severity of adverse events (AEs) and serious adverse events (SAEs)|Dose interruptions and reductions|Dose intensity</td>
              <td>Incidence of DLTs in Cycle 1 (28 days) in escalation and expansion; Dose intensity as a ratio of cumulative dose received during duration of exposure over duration of exposure for NIZ985 spartalizumab and tislelizumab.; Number of dose interruptions and dose reductions of NIZ985 spartalizumab and tislelizumab.; AEs and SAEs including changes in laboratory parameters vital signs and electrocardiograms (ECGs) qualifying and reported as AEs for all patients from escalation and expansion</td>
              <td>1 cycle (28 days); 24 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_9" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
      <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class="modal-body">
        <table class="table table-striped">
          <thead>
            <tr>
              <th colspan="1">Arm Group Type</th>
              <th colspan="1">Arm Group Description</th>
              <th colspan="1">Arm Group Intervention</th>
              <th colspan="1">Primary Outcome Measure</th>
              <th colspan="1">Primary Outcome Description</th>
              <th colspan="1">Primary Outcome Time Frame</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td></td>
              <td></td>
              <td></td>
              <td>Modification(s) in the immune blood markers of treated subjects on treatment.|Modification(s) in the immune blood markers of treated subjects on treatment.|Modification(s) in the immune blood markers of treated subjects on treatment.|Modification(s) in the immune blood markers of treated subjects on treatment at the occurence of any grade 1 or 2 irAE.|Modification(s) in the immune blood markers of treated subjects on treatment at the occurence of any grade 3 or 4 irAE.</td>
              <td>Safety will be assessed and graded by the investigator(s) by using the adverse events reported during the study in accordance with the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.; Modification(s) in the immune blood markers including cytokines immune cells and serum autoantibody level of treated subjects.</td>
              <td>Assessment: between week 8 and 11 after the first dose of the treatment; Assessment: between week 13-18 after the first dose of the treatment; Assessment: between week 4 and 6 after the first dose of the treatment; Assessment: Day one after diagnostic of any grade 3 or 4 irAE; Assessment: Day1 after diagnostic of any grade 1 or 2 irAE</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_10" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
      <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class="modal-body">
        <table class="table table-striped">
          <thead>
            <tr>
              <th colspan="1">Arm Group Type</th>
              <th colspan="1">Arm Group Description</th>
              <th colspan="1">Arm Group Intervention</th>
              <th colspan="1">Primary Outcome Measure</th>
              <th colspan="1">Primary Outcome Description</th>
              <th colspan="1">Primary Outcome Time Frame</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td>Experimental</td>
              <td>ZN-c3 in combination with bevacizumab|ZN-c3 in combination with bevacizumab and pembrolizumab</td>
              <td>Drug: Bevacizumab; Drug: ZN-c3; Drug: Pembrolizumab</td>
              <td>To establish the maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) of ZN-c3 .|To establish the maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) ZN-c3 and bevacizumab.</td>
              <td></td>
              <td>through study completion an average of 1 year</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_11" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
      <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class="modal-body">
        <table class="table table-striped">
          <thead>
            <tr>
              <th colspan="1">Arm Group Type</th>
              <th colspan="1">Arm Group Description</th>
              <th colspan="1">Arm Group Intervention</th>
              <th colspan="1">Primary Outcome Measure</th>
              <th colspan="1">Primary Outcome Description</th>
              <th colspan="1">Primary Outcome Time Frame</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td>Experimental</td>
              <td>OT-101 will be administered at a RP2D dose/m2/day for 4 days continuously and 10 days off every two weeks via a portable infusion pump.||Pembrolizumab will be administered with the standard regimen of 400 mg intravenously (IV) every six weeks.</td>
              <td>Drug: OT-101</td>
              <td>Determination of ORR for the combination of OT-101 and pembrolizumab in subjects</td>
              <td>modified RECIST (mRECIST; v1.1)</td>
              <td>approximately 24 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_12" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
      <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class="modal-body">
        <table class="table table-striped">
          <thead>
            <tr>
              <th colspan="1">Arm Group Type</th>
              <th colspan="1">Arm Group Description</th>
              <th colspan="1">Arm Group Intervention</th>
              <th colspan="1">Primary Outcome Measure</th>
              <th colspan="1">Primary Outcome Description</th>
              <th colspan="1">Primary Outcome Time Frame</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td>Experimental</td>
              <td>Dose escalation of rSIFN-co</td>
              <td>Biological: rSIFN-co</td>
              <td>Maximum Tolerated Dose</td>
              <td></td>
              <td>28-days</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- ############################### -->
<!-- ############################### -->
<!-- ######## FDA APPROVALS ######## -->
<!-- ############################### -->
<!-- ############################### -->

<br>
<h2 id="approvals">Drug Approvals/Applications</h2>
<h4><a href="#home">Home</a></h4>
<table border="1" summary="Long-term goals table" width="100%" cellspacing="0" cellpadding="0">
  <thead>
    <tr>
      <th>
        <h3>Company</h3>
      </th>
      <th>
        <h3>Update</h3>
      </th>
      <th>
        <h3>Trial ID</h3>
      </th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Prestige Biopharma</td>
      <td>US FDA Approves Prestige Biopharmas IND for Phase 1/2a Trial of First-in-Class Pancreatic Cancer Treatment PBP1510</td>
      <td>NCT05141149</td>
    </tr>
    <tr>
      <td>Bristol Meyers Squibb</td>
      <td>Amidst Legal Battle BMS' Car-T Therapy Scores Second FDA Approval</td>
      <td>TRANSFORM (NCT03575351)</td>
    </tr>
    <tr>
      <td>Novartis</td>
      <td>Novartis Tafinlar + Mekinist receives FDA approval for first tumor-agnostic indication for BRAF V600E solid tumors</td>
      <td>ROAR√Ç¬†(NCT02034110)</td>
    </tr>
    <tr>
      <td>Ellipses Pharma</td>
      <td>Ellipses Announces FDA Clearance of IND Application for EP0031 for Patients With Advanced RET-altered Malignancies</td>
      <td></td>
    </tr>
    <tr>
      <td>Fusion Pharmaceuticals</td>
      <td>Fusion Pharmaceuticals Announces FDA Clearance of IND for FPI-2059 an Investigational Small Molecule-Based Radiopharmaceutical Targeting Solid Tumors Expressing NTSR1</td>
      <td></td>
    </tr>
    <tr>
      <td>Nuvectis Pharma</td>
      <td>Nuvectis Pharma Announces FDA Clearance of IND for NXP800</td>
      <td></td>
    </tr>
    <tr>
      <td>AstraZeneca</td>
      <td>Trastuzumab Deruxtecan Recommended for Approval in the EU by CHMP for Patients with HER2 Positive Metastatic Breast Cancer Treated with a Prior Anti-HER2-Based Regimen</td>
      <td>DESTINY-Breast03 (NCT03529110)</td>
    </tr>
    <tr>
      <td>Novartis</td>
      <td>EMA's CHMP Recommends Novartis' Scemblix for TKI-Intolerant Chronic Myeloid Leukemia Patients</td>
      <td>ASCEMBL (NCT03106779)</td>
    </tr>
    <tr>
      <td>AstraZeneca</td>
      <td>LYNPARZA (olaparib) Receives Positive Opinion From EU CHMP as Adjuvant Treatment for Germline BRCA-Mutated HER2-Negative High-Risk Early Breast Cancer</td>
      <td>OlympiA (NCT02032823)</td>
    </tr>
  </tbody>
</table>
<br>
<p><strong> <em>Disclaimer: This weekly digest is a product created exclusively by Lexidyne LLC, in collaboration with Janssen. The intended purpose is to identify clinical phase assets with new data related to lung cancer, priority mechanisms of action, local/intratumoral delivery, and/or increased potency for acquisition & business development consideration. </em> </strong></p>
<p><em>Sources used include but are not limited to: PubMed, ClinicalTrials.gov, ASCO, AACR, NIH, EU Clinical Trials Register, European Pharmaceutical Review, FDA.gov, PRNewsWire, FiercePharma, and BioSpace. </em> </p>